MERCAPTOPURINE ANHYDROUS
Mixed Gliomas
Emory UniversitySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Mixed Gliomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BBB |
Temsirolimus Andrew B Lassman, MD | Phase 1/2 | B |
Perifosine Andrew B Lassman, MD | Phase 1/2 | B |
Veliparib National Cancer Institute (NCI) | Phase 1/2 | B |
CARMUSTINE Emory University | Phase 2 | B |
View all 39 →
Same molecule, other indications
MERCAPTOPURINE ANHYDROUS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →